Advertisement

Canadian Journal of Public Health

, Volume 93, Issue 6, pp 443–446 | Cite as

An Epidemiologic Study of Hepatocellular Carcinoma in Canada

  • Susie ElSaadanyEmail author
  • Martin Tepper
  • Yang Mao
  • Robert Semenciw
  • Antonio Giulivi
Article

Abstract

Background and Methods: To provide information on poorly described Canadian hepatocellular cancer epidemiology, we analyzed incident cases abstracted from the Canadian Cancer Registration Database (1969–1997) and Canadian annual death data (1969–1998). Age, sex, geographic distribution, and secular trends were described. Projection models were developed for the next decade.

Results: Results indicated much higher incidence and mortality rates in males than females, with substantial increases for both with age. Age-standardized incidence rates increased an average of 3.4% per year in males, 1.2% per year in females (1969–1997). Age-standardized mortality rates increased an average of 1.48% in males, but decreased an average of 0.46% per year in females (1969–1998). Joinpoint analysis of the linear trends in the age-standardized incidence and mortality rates suggested that a new trend started to emerge about 1991. The fitted non-linear multiplicative model predicted the occurrence of 1,565 new cases and 802 deaths in the year 2010. HCC incidence was the highest in British Colombia, followed by Quebec, and the lowest in the Atlantic region.

Conclusions: Incidence rates of hepatocellular carcinoma have increased substantially, consistent with the reported increase in the prevalence of Hepatitis C Virus (HCV) and Hepatitis B Virus (HBV) infections in recent decades.

Résumé

Contexte et méthodes: Afin de combler le manque d’information sur l’épidémiologie du cancer hépatocellulaire au Canada, qui a été peu décrite jusqu’à maintenant, nous avons analysé les nouveaux cas tirés de la base de données du Registre canadien du cancer (1969–1997) et les données annuelles sur la mortalité au Canada (1969–1998). L’âge, le sexe, la répartition géographique et les tendances à long terme ont fait l’objet d’une description. Des modèles de projection ont été élaborés pour la prochaine décennie.

Résultats: Les résultats indiquent des taux d’incidence et de mortalité beaucoup plus élevés chez les hommes que chez les femmes. Pour les hommes comme pour les femmes, on observe une importante croissance des taux avec l’âge. Les taux d’incidence normalisés selon l’âge ont augmenté en moyenne de 3,4% par année chez les hommes et de 1,2% par année chez les femmes (1969–1997). Les taux de mortalité normalisés selon l’âge ont augmenté en moyenne de 1,48% chez les hommes, mais ont diminué en moyenne de 0,46% par année chez les femmes (1969–1998). L’analyse par point de retournement des tendances linéaires des taux d’incidence et de mortalité normalisés selon l’âge suggère l’émergence d’une nouvelle tendance vers 1991. Le modèle multiplicatif non linéaire ajusté prévoit la survenue de 1 565 nouveaux cas et de 802 décès en 2010. C’est en Colombie-Britannique, suivie du Québec, qu’on trouve l’incidence la plus élevée de CHC, alors que l’incidence la plus basse s’observe dans la région de l’Atlantique.

Conclusions: Les taux d’incidence du carcinome hépatocellulaire ont augmenté de façon notable, ce qui est compatible avec l’augmentation signalée de la prévalence de l’infection par le virus de l’hépatite C (VHC) et de l’infection par le virus de l’hépatite B (VHB) dans les dernières décennies.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Aoki K, Hayakawa N, Kurihara M, Suziki S. Death rates for malignant neoplasms for selected sites by sex and five-year age groups in 33 countries, 1953–57 to 1983–87. Nagoya: University of Nagoya Coop Press, 1992.Google Scholar
  2. 2.
    McLaughlin JR, Sloan MR, Janovjak DP. Cancer Survival in Ontario. Toronto: The Ontario Cancer Treatment and Research Foundation, 1995.Google Scholar
  3. 3.
    Holford TR. Understanding the effects of age, period, and cohort on incidence and mortality rates. Annu Rev Public Health 1991;12:425–57.CrossRefGoogle Scholar
  4. 4.
    Holford TR. Analysing the effects of age, period, and cohort on incidence and mortality rates. Stat Meth Med Res 1992;1:317–37.CrossRefGoogle Scholar
  5. 5.
    MacNeill IB. Projection Methods Age-Period Cohort Cancer Data. Internal Technical Report. Ottawa: Cancer Bureau, Health Canada, 1995.Google Scholar
  6. 6.
    MacNeill IB, Mao Y, Xie L, Tang SM. Segmented models for age-period cohort cancer data. Int J Mathematical and Statistical Sci 1995;4:1–10.Google Scholar
  7. 7.
    Joinpoint Regression Program [computer program]. Version 2.3. Washington: National Cancer Institute, 2000.Google Scholar
  8. 8.
    Mathsoft. S-plus 2000 Guide to Statistics, Volume 1. Seattle, WA: Data Analysis Products Division, Mathsoft, 1999.Google Scholar
  9. 9.
    Donato F, Boffetta P, Puoti MA. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998;75:347–54.CrossRefGoogle Scholar
  10. 10.
    Shiratori Y, Shiina S, Zhang PY, Ohno E, Okudaria T, Payawal DA, et al. Does dual infection by hepatitis B and C viruses play an important role in the pathogenesis of hepatocellular carcinoma in Japan? Cancer 1997;80:2060–67.CrossRefGoogle Scholar
  11. 11.
    Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:1797–801.CrossRefGoogle Scholar
  12. 12.
    Chang CC, Yu MW, Lu CF, Yang CS, Chen CJ. A nested case-control study on association between hepatitis C virus antibodies and primary liver cancer in a cohort of 9,775 men in Taiwan. J Med Virol 1994;43:276–80.CrossRefGoogle Scholar
  13. 13.
    Mori M, Hara M, Wada I, Hara T, Yamamoto K, Honda M, et al. Prospective study of hepatitis B and C viral infections, cigarette smoking, alcohol consumption, and other factors associated with hepatocellular carcinoma risk in Japan. Am J Epidemiol 2000;151:131–39.CrossRefGoogle Scholar
  14. 14.
    Corrao G, Ferrari P, Zambon A, Torchio P, Arico S, Decarli A. Trends of liver cirrhosis mortality in Europe, 1970–1989: Age-period-cohort analysis and changing alcohol consumption. Int J Epidemiol 1997;26:100–9.CrossRefGoogle Scholar
  15. 15.
    Statistics Canada. Health Status of Canadians: Report of the 1991 General Social Survey. Ottawa: Minister of Industry, Science and Technology, 1994;127–35. Catalogue No. 11-612E, No. 8.Google Scholar
  16. 16.
    Statistics Canada. National Population Health Survey 1994–95 Public Use Microdata Files (CD-ROM). Ottawa: Minister of Industry, Science and Technology, 1995. Catalogue No. 82F0001XCB.Google Scholar
  17. 17.
    Statistics Canada. National Population Health Survey 1996–97 Public Use Microdata Files (CD-ROM). Ottawa: Minister of Industry, Science and Technology, 1998. Catalogue No. 82M0009XCB.Google Scholar
  18. 18.
    Smart RG, Suurvali HM, Mann RE. Do drinking surveys predict changes in population-based alcohol problem indicators? Alcohol 2000;35(3):255–58.CrossRefGoogle Scholar
  19. 19.
    Tepper M, ElSaadany S. Hepatocellular Carcinoma in Canada: Whither Goest. CASL Single Topic Conference on Hepatocellular Carcinoma–Science and Practice, June 26–27, 1998, Niagara-on the Lake, Canada.Google Scholar
  20. 20.
    Smart RG, Mann RE. Treatment, Alcoholics Anonymous and alcohol controls during the decrease in alcohol problems in Alberta: 1975–1993. Alcohol 1998;33(3):265–72.CrossRefGoogle Scholar
  21. 21.
    Health Canada, Blood Borne Pathogens Division. Viral hepatitis and emerging bloodborne pathogens in Canada. Can Commun Dis Rep 2001;27(S3).Google Scholar
  22. 22.
    Health Canada, Blood Borne Pathogens Division. Study on the Immigration from HBV and HCV Areas in Canada. Unpublished Report. Ottawa, Blood Borne Pathogens Division, 1998.Google Scholar
  23. 23.
    Zou S, Tepper M, Giulivi A. Current status of hepatitis C in Canada. Can J Public Health 2000;91(Suppl. 1):S10–S15.PubMedGoogle Scholar
  24. 24.
    Zou S, Tepper M, ElSaadany S. Prediction of hepatitis C burden in Canada. Can J Gastroenterology 2000;14(7):575–80.CrossRefGoogle Scholar
  25. 25.
    Health Canada, Blood Borne Pathogens Division. Current Status of Hepatitis B in Canada. Internal Report. Ottawa: Blood Borne Pathogens Division, 2000.Google Scholar
  26. 26.
    Collier J, Sherman M. Screening for hepatocellular carcinoma. Hepatology 1998;27(1):273–78.CrossRefGoogle Scholar
  27. 27.
    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340(10):745–50.CrossRefGoogle Scholar
  28. 28.
    Deuffic S, Poynard T, Buffat L, Valleron AJ. Trends in primary liver cancer. Lancet 1998;351:214–15.CrossRefGoogle Scholar
  29. 29.
    Dinse GE, Umbach DM, Sasco AJ, Hoel DG, Davis DL. Unexplained increases in the cancer incidence in the United States from 1975–1994: Possible sentinel health indicators. Annu Rev Public Health 1999;20:173–209.CrossRefGoogle Scholar

Copyright information

© The Canadian Public Health Association 2002

Authors and Affiliations

  • Susie ElSaadany
    • 1
    Email author
  • Martin Tepper
    • 2
  • Yang Mao
    • 3
  • Robert Semenciw
    • 3
  • Antonio Giulivi
    • 1
  1. 1.Health-Care Acquired Infections DivisionHealth CanadaOttawaCanada
  2. 2.Office of Public Health SecurityHealth CanadaCanada
  3. 3.Surveillance and Risk Assessment DivisionHealth CanadaCanada

Personalised recommendations